Serology for trachoma surveillance after cessation of mass drug administration - Test2 - elhamkhani - TriplyDB

Serology for trachoma surveillance after cessation of mass drug administration

Serology for trachoma surveillance after cessation of mass drug administration

http://www.wikidata.org/entity/Q28543658

about

Mass drug administration of azithromycin for trachoma reduces the prevalence of genital Chlamydia trachomatis infection in the Solomon Islands Current Mathematical Models for Analyzing Anti-Malarial Antibody Data with an Eye to Malaria Elimination and Eradication Trachoma and Yaws: Common Ground?Control of Trachoma from Achham District, Nepal: A Cross-Sectional Study from the Nepal National Trachoma Program The Relationship between Active Trachoma and Ocular Chlamydia trachomatis Infection before and after Mass Antibiotic Treatment Cross-Sectional Surveys of the Prevalence of Follicular Trachoma and Trichiasis in The Gambia: Has Elimination Been Reached?Low Prevalence of Ocular Chlamydia trachomatis Infection and Active Trachoma in the Western Division of Fiji Possible changes in the transmissibility of trachoma following MDA and transmission reduction: implications for the GET2020 goals.Multiple comparisons analysis of serological data from an area of low Plasmodium falciparum transmission.Defining Seropositivity Thresholds for Use in Trachoma Elimination Studies.Killing of diverse eye pathogens (Acanthamoeba spp., Fusarium solani, and Chlamydia trachomatis) with alcohols.Serological Measures of Trachoma Transmission Intensity Sample size and power calculations for detecting changes in malaria transmission using antibody seroconversion rate.Analysis of age-dependent trends in Ov16 IgG4 seroprevalence to onchocerciasis.Anti-malarial seroprevalence assessment during an elimination programme in Chabahar District, south-eastern Iran.Antibody acquisition models: A new tool for serological surveillance of malaria transmission intensity.The World Health Organization Recommendations for Trachoma Surveillance, Experience in Nepal and Added Benefit of Testing for Antibodies to Chlamydia trachomatis pgp3 Protein: NESTS Study.Community seroprevalence survey for yaws and trachoma in the Western Division of Fiji.Prevalence of signs of trachoma, ocular Chlamydia trachomatis infection and antibodies to Pgp3 in residents of Kiritimati Island, Kiribati.Surveillance Surveys for Reemergent Trachoma in Formerly Endemic Districts in Nepal From 2 to 10 Years After Mass Drug Administration Cessation.Serology reflects a decline in the prevalence of trachoma in two regions of The Gambia.Comparison of Platforms for Testing Antibody Responses against the Chlamydia trachomatis Antigen Pgp3.Prevalence of Chlamydia trachomatis-Specific Antibodies before and after Mass Drug Administration for Trachoma in Community-Wide Surveys of Four Communities in Nepal.Active Trachoma Cases in the Solomon Islands Have Varied Polymicrobial Community Structures but Do Not Associate with Individual Non-Chlamydial Pathogens of the Eye.Longitudinal change in the serology of antibodies to Chlamydia trachomatis pgp3 in children residing in a trachoma area.Latent class modeling to compare testing platforms for detection of antibodies against the Chlamydia trachomatis antigen Pgp3.Clinical signs of trachoma are prevalent among Solomon Islanders who have no persistent markers of prior infection with Chlamydia trachomatis.

P2860

Q24658574-8371DA89-5395-4FF8-B62E-E516C692BF70 Q26771746-3E478F04-AC84-4D8B-B86E-CD01D6BCF68F Q26775120-992CF9C5-D1FF-494C-B5E4-C2B6BA69F76B Q28550184-B901C6A2-DE89-4886-837E-327D23D04378 Q28552982-EC098B7B-184D-4182-952E-4EA1904F0542 Q28554221-6540A233-2C14-4503-A26B-FF6D5860F754 Q28596379-7FB1644A-C810-4191-AC21-7B427D2EF97D Q30670495-8ED6B1C2-3BB1-4846-9D5C-555BEDD0D62A Q31018004-6F4A67A6-E4EB-4A84-A03E-0C4BBB046D1B Q36252526-EA273A64-1860-461D-A39D-047C25FD5EC0 Q36275338-EE36662B-7901-4B0E-A972-C1E585EDDA98 Q36387948-0B04A39C-7080-4713-95ED-C24F9F9F66D0 Q36417089-78DE4FEC-0688-4894-8D1E-68F76549550A Q37002594-A7CD5155-29F9-4FDE-8B28-A55219028308 Q37119475-CF5D5364-1659-4760-B820-91B1F798A050 Q37175027-56C71FA0-084C-4F5D-8B49-0AE7E64F2799 Q37273038-347A48D1-F099-46DB-AD5F-C341996ED062 Q37502255-7AC3BEEE-E0F3-4676-B9D0-D82D2E2E5C7A Q40045638-C63880C5-B315-422B-92F1-043407F5ECC1 Q41991604-3C0EE31F-F0B4-4E79-ABE1-6F3EF80020F5 Q43366299-06178FFB-6782-4FF3-B8FF-DC2EF271FC3D Q43924390-C214BB17-8775-4368-9E19-B0605D2FE5E1 Q44059336-9D26000A-B265-4CF9-8C23-C60FBD9E036A Q48499619-6BA7F850-5652-4465-87BD-1C297CB8FF70 Q50335721-D6D999AB-AE0D-43E8-98E2-52FA9895BD67 Q52663583-28CB8795-77A0-4D7F-84EB-15E4411782EE Q54943022-F556D25C-7BBF-45DA-B8F6-41C83D9556A6

P2860

Serology for trachoma surveillance after cessation of mass drug administration

http://www.wikidata.org/entity/Q28543658

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Serology for trachoma surveillance after cessation of mass drug administration

@ast

Serology for trachoma surveillance after cessation of mass drug administration

@en

Serology for trachoma surveillance after cessation of mass drug administration

@nl

type

label

Serology for trachoma surveillance after cessation of mass drug administration

@ast

Serology for trachoma surveillance after cessation of mass drug administration

@en

Serology for trachoma surveillance after cessation of mass drug administration

@nl

prefLabel

Serology for trachoma surveillance after cessation of mass drug administration

@ast

Serology for trachoma surveillance after cessation of mass drug administration

@en

Serology for trachoma surveillance after cessation of mass drug administration

@nl

P1433

Q28543658-7C192C3F-B260-460D-81A8-768672F6231C

P1476

Q28543658-8741F74F-4AF0-47C3-9A2D-0DB879151387

P2093

Q28543658-0C7FBD68-74D6-408C-B3EB-1A5721DC7244

Q28543658-420045D8-B1B2-413C-95C0-4F41A2694598

Q28543658-54DA04ED-9B81-4E79-AC0C-570CF179565F

Q28543658-5ACE0B03-89A0-44C7-BCA7-3A23119E3DD5

Q28543658-A6560CDD-CAAB-4DDE-8B6E-9507C76C901C

Q28543658-B3544F57-5075-4F76-BBE8-A5967F1BE53D

Q28543658-D5878726-CB35-45D4-A0DB-927F11A3F7B5

Q28543658-E580C0DF-9FA6-4E08-82DA-17FA15B22C49

P275

Q28543658-F8520B15-045E-413B-8365-9886B2235D58

P2860

Q28543658-0445571F-A3F0-4C20-9782-D4D91FB2053C

Q28543658-103D65B7-6A36-4FD5-9D7B-806AC1E5AADD

Q28543658-2916CE38-DC7B-4D20-A0C8-423436E33EBD

Q28543658-4B7ED2F8-511C-4BCB-A3D3-6DF4E9002137

Q28543658-4FC61D5F-3E5B-4C1B-84EC-A470EF1DB3BA

Q28543658-53278C21-0913-4323-AC74-47F50C25754F

Q28543658-558B99CC-5EB0-49F8-AA86-159E5E7758ED

Q28543658-55C6C5C4-2115-4371-B794-6447FDC4ADB0

Q28543658-579B0CFC-BA69-47F5-BE38-B68785932A6D

Q28543658-58339F76-CE22-428E-8937-B0217A0AE12C

P304

Q28543658-514FE612-E5DD-4D2B-BE58-AD3B2B721417

P31

Q28543658-0E9FA968-7405-4244-AE66-162AA434E0E6

P3181

Q28543658-B32519A4-E2A7-4A93-9971-8FE66E2AC41E

P356

Q28543658-7DCBF76F-24B1-4496-8818-0DC94DBF54C3

P407

Q28543658-5EF3C3E0-37C6-4317-9452-52D6363053DA

P433

Q28543658-C15C19D1-2D75-4CE6-8ACA-ED4304A4A916

P478

Q28543658-01437995-FCB9-47B2-A73A-56B394101309

P50

Q28543658-1C0F1B9D-67D7-4BE3-A3C2-5450F006A355

Q28543658-5E952B31-7D34-4E19-9D1B-15CA37A374C3

Q28543658-90A94F84-A93F-4735-AFD9-E1903FBA2429

Q28543658-BFF84B45-C78A-4EF8-A811-B0B2CBD781EE

Q28543658-C63B0A89-E166-4EFA-9A5E-FC2CCB323298

Q28543658-FD5B033F-E6C5-4C49-BF5B-3E8C2865D055

P5008

Q28543658-B5DA7AA8-69B1-4C9F-8F7B-E00E26B8B6FA

P577

Q28543658-78D6D072-C2CE-4EF7-9F11-B41685DA9D38

P5875

Q28543658-7AA5FC9C-498F-4F46-8E47-58E3C412EF63

P698

Q28543658-98668AD8-F2A7-4410-93C4-BE49759FB6F9

P921

Q28543658-C6EA4B53-2DA2-45CE-8052-5FCF5C3BDAF3

P932

Q28543658-408362EF-A317-423D-8DD8-3560C0B35BF3

P3181

P356

JOURNAL.PNTD.0003555

P1433

PLOS Neglected Tropical Diseases

P1476

Serology for trachoma surveillance after cessation of mass drug administration

@en

P2093

Augustin Lasway

http://www.w3.org/2001/XMLSchema#string

Diana L Martin

http://www.w3.org/2001/XMLSchema#string

E Brook Goodhew

http://www.w3.org/2001/XMLSchema#string

Frank Sandi

http://www.w3.org/2001/XMLSchema#string

Patrick A Massae

http://www.w3.org/2001/XMLSchema#string

Rhiannon Bid

http://www.w3.org/2001/XMLSchema#string

Sandra Molina

http://www.w3.org/2001/XMLSchema#string

William Makupa

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

A simple system for the assessment of trachoma and its complications

Spatial Evaluation and Modeling of Dengue Seroprevalence and Vector Density in Rio de Janeiro, Brazil

A multicenter evaluation of diagnostic tools to define endpoints for programs to eliminate bancroftian filariasis

CT694 and pgp3 as serological tools for monitoring trachoma programs

Incidence of symptomatic and asymptomatic Leishmania donovani infections in high-endemic foci in India and Nepal: a prospective study.

Longitudinal analysis of antibody responses to trachoma antigens before and after mass drug administration

Clinical activity and polymerase chain reaction evidence of chlamydial infection after repeated mass antibiotic treatments for trachoma

Profound and sustained reduction in Chlamydia trachomatis in The Gambia: a five-year longitudinal study of trachoma endemic communities

Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure

Using serological measures to monitor changes in malaria transmission in Vanuatu

P304

e0003555

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3969

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PNTD.0003555

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Heiko Philippin

Anthony W Solomon

Martin J Holland

Chris J Drakeley

Patrick J Lammie

P5008

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272839381

http://www.w3.org/2001/XMLSchema#string

P698

25714363

http://www.w3.org/2001/XMLSchema#string

P921

infectious disease

P932

4340913

http://www.w3.org/2001/XMLSchema#string